Abstract 668: The translational biology of small molecule GPR65 inhibitors: shared effects between mouse models and human primary tumors highlight the unique transformative potential of targeting a genetically validated innate immune checkpoint
Barbara Cipriani, Stuart W. Hughes, Nandini Pal Basak(Anthem Biosciences (India)), Gavin Knox, Alastair Corbin, T. G. McCarthy, Satish Sankaran(Anthem Biosciences (India)), Toszka Bohn(Johannes Gutenberg University Mainz), Tobia Bopp(Johannes Gutenberg University Mainz), Anastasia Nika, Surya Koturan(University of Oxford), Mussa Quareshy, Bo Sun(University of Oxford), Alan Naylor(GlaxoSmithKline (United Kingdom)), Benjamin P. Fairfax(University of Oxford), Rupert Satchell, David Miller(University of Leeds), Sourav Sarkar, Barbara Young, Faraz Khan, Darryl Turner, Preeti Singh(Indian Agricultural Statistics Research Institute), Gavin Milne
Cited by 3
Related Papers
Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis
|bioRxiv (Cold Spring Harbor Laboratory)|2018|546
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
|Cell Reports|2019|297
Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo
|Nature Immunology|2015|111
Germline variants associated with toxicity to immune checkpoint blockade
|Nature Medicine|2022|109
A toolbox for surfacing health equity harms and biases in large language models
|Nature Medicine|2024|96